Evidence map›Paper›PMID 41256841›Full record

ArticleFrontiers in immunology2025

Is there an alternative to the indirect immunofluorescence ANA HEp-2 assay for the diagnosis of connective tissue diseases?

Tamazouzt Hadjout, Lydia Lamara Mahammed, Meriem Saad, Amel Zemmour, Nadia Tamechmacht, Ghalya Bousbia, Halima Ismail, Nawel Dahmani, Ines Allam, Reda Djidjik

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tamazouzt Hadjout *Department of Medical Immunology, Beni Messous University Hospital Center, Algiers, Algeria.
Lydia Lamara Mahammed *Department of Medical Immunology, Beni Messous University Hospital Center, Algiers, Algeria.
Meriem SaadDepartment of Medical Immunology, Beni Messous University Hospital Center, Algiers, Algeria.
Amel ZemmourDepartment of Medical Immunology, Beni Messous University Hospital Center, Algiers, Algeria.
Nadia TamechmachtDepartment of Medical Immunology, Beni Messous University Hospital Center, Algiers, Algeria.
Ghalya BousbiaDepartment of Medical Immunology, Beni Messous University Hospital Center, Algiers, Algeria.
Halima IsmailDepartment of Medical Immunology, Beni Messous University Hospital Center, Algiers, Algeria.
Nawel DahmaniDepartment of Medical Immunology, Beni Messous University Hospital Center, Algiers, Algeria.
Ines AllamDepartment of Medical Immunology, Beni Messous University Hospital Center, Algiers, Algeria.
Reda DjidjikDepartment of Medical Immunology, Beni Messous University Hospital Center, Algiers, Algeria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Anti-nuclear antibodies (ANA) are serological hallmarks in the diagnosis of ANA-associated rheumatic diseases (AARD). For many years, indirect immunofluorescence (IIF) on HEp-2 cell substrate has been regarded as the gold standard method for ANA detection. Nowadays, several solid phase immunoassays (SPA) have been developed for ANA screening. The aim of this study was to evaluate three automated assays as potential alternatives to the IIF HEp-2 assay for ANA detection in the diagnosis of AARD. Patients and methods: This study included 271 patients referred to our department for routine ANA testing: 94 patients with confirmed AARD, 144 in whom AARD was excluded and 33 with an uncertain AARD diagnosis. For all sera, ANA detection was initially performed using an IIF HEp-2 assay (EUROIMMUN Results: The highest positivity rate was found with the MAGLUMI in the AARD group, with the highest concordance rate with IIF (77.9% Conclusion: These findings suggest that SPA can serve as a complementary approach to IIF for ANA screening in the diagnosis of AARD. The MAGLUMI assay could be used for initial screening alongside IIF, depending on the clinical context. A proper adjustment of the threshold of the MAGLUMI ANA Screen assay may improve its specificity and limit false positive results.

Indexed as

Antibodies, AntinuclearConnective Tissue DiseasesAdultAgedFemaleFluorescent Antibody Technique, IndirectHumansImmunoassayMaleMiddle AgedSensitivity and SpecificityYoung AdultAntibodies, AntinuclearANA-associated rheumatic diseasesanti-nuclear antibodieschemiluminescenceIIFsolid phase immunoassays

Identifiers

PMID41256841
PMCPMC12620368

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.